TB-500: Identity, Evidence, and Documentation

TB-500 is cataloged here as a thymosin-β4 fragment research peptide. TB-500 is used in current FDA materials for the N-acetylated seven-amino-acid sequence LKKTETQ, a fragment corresponding to residues 17–23 of full-length thymosin β4.

Identity before interpretation

“TB-500,” “TB4,” full-length thymosin β4, and the LKKTETQ fragment are not interchangeable names. A lot record must identify which molecular species was actually analyzed.

A short catalog name is a starting point, not a complete material characterization. Reproducible work begins by matching the named material to its sequence or chemical form, SKU, lot, nominal quantity, analytical method, and the actual result reported for that sample.

Research questions in the literature

• Actin-binding-domain behavior and cell migration in controlled model systems.
• Endothelial sprouting, matrix remodeling, and repair-associated assays.
• Differences between full-length thymosin β4 literature and fragment-specific experiments.

These topics describe what investigators measured. They should not be converted into treatment language, consumer promises, or an assumption that a finding transfers across species, tissues, preparations, or experimental conditions.

Evidence map

• A 2003 study linked the central actin-binding motif of thymosin β4 to endothelial migration and sprouting assays.
• A separate 2003 animal study evaluated full-length thymosin β4 and the LKKTETQ fragment in wound-repair models.
• Results obtained with full-length thymosin β4 cannot automatically be assigned to a shorter fragment or to a catalog item with an unverified sequence.

Evidence strength depends on the question. A receptor assay can inform target engagement; a cell model can inform a pathway hypothesis; an animal model can inform a defined biological system. None of those alone proves clinical safety, effectiveness, or suitability of a separately sourced material.

Interpretation guardrails

• Published repair-related findings are largely cellular or animal-model observations and are not personal-use guidance.
• Identity ambiguity is a central interpretation risk; the lot-specific sequence and form must be confirmed.
• This Vespera record makes no claim of clinical safety, efficacy, sterility, or suitability for administration.

Vespera does not translate this literature into dosing, reconstitution, injection, route-of-use, diagnosis, treatment, or veterinary guidance. If a project requires those claims, this catalog and this brief are not the appropriate source.

Lot and COA review

• Confirm whether the specification identifies the seven-residue fragment, full-length thymosin β4, or another related material.
• Match sequence/form, SKU, strength, lot, method, and reported mass or purity information.
• Keep literature on full-length and fragment materials separated in the research record.

Chromatographic purity, mass confirmation, quantity, endotoxin, microbial controls, residual solvents, water content, and stability answer different questions. A single headline percentage should not be used as a universal quality score.

Primary and official sources

Read the methods, model, material description, limitations, and conflicts of interest in the source itself.

1. FDA briefing document — TB-500-related bulk drug substances (2026)Identity discussion distinguishing TB-500 from full-length thymosin β4.
2. Malinda et al. — thymosin β4 actin-binding site and angiogenesis assays (2003)Cell migration and vessel-sprouting model systems.
3. Philp et al. — thymosin β4 and LKKTETQ in animal wound models (2003)Animal-model study; not evidence of human use.